Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1RMS5
|
|||
| Drug Name |
OTL-300
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Beta thalassemia [ICD-11: 3A50.2; ICD-10: D56.1, D56.3] | Phase 1/2 | [1] | |
| Company |
Orchard Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03275051) Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Orchard Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.